(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 12.42%
Live Chart Being Loaded With Signals
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U...
Stats | |
---|---|
今日成交量 | 2.91M |
平均成交量 | 2.57M |
市值 | 238.60M |
EPS | $0 ( 2024-02-08 ) |
下一个收益日期 | ( $-0.0600 ) 2024-05-08 |
Last Dividend | $0.0700 ( 2014-04-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.33 |
ATR14 | $0.00800 (0.49%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-02 | Rankowitz Michael L | Buy | 90 000 | Common Stock Option |
2023-10-02 | Eisenberger Mario | Buy | 70 000 | Common Stock Option |
2023-10-02 | Lu Lucy | Buy | 80 000 | Common Stock Option |
2023-10-02 | Hyun Grace | Buy | 60 000 | Common Stock Option |
2023-05-09 | Greco Michele | Buy | 104 000 | Common Stock Option |
INSIDER POWER |
---|
94.78 |
Last 100 transactions |
Buy: 7 521 942 | Sell: 795 000 |
音量 相关性
Veru Inc 相关性 - 货币/商品
Veru Inc 财务报表
Annual | 2023 |
营收: | $16.30M |
毛利润: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2023 |
营收: | $16.30M |
毛利润: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2022 |
营收: | $39.35M |
毛利润: | $30.59M (77.73 %) |
EPS: | $-1.050 |
FY | 2021 |
营收: | $61.26M |
毛利润: | $47.93M (78.24 %) |
EPS: | $0.100 |
Financial Reports:
No articles found.
Veru Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2010-01-27 |
Last Dividend | $0.0700 | 2014-04-28 |
Next Dividend | $0 | N/A |
Payout Date | 2014-05-07 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $1.040 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.68 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0.200 | 4.14% |
2011 | $0.200 | 3.50% |
2012 | $0.230 | 4.87% |
2013 | $0.270 | 3.69% |
2014 | $0.140 | 1.67% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -4.05 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.801 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.14 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.58 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.44 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.133 | -1.500 | 7.78 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -36.67 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.591 | 2.00 | -0.197 | -0.394 | [0 - 30] |
freeCashFlowPerShareTTM | -0.595 | 2.00 | -0.298 | -0.595 | [0 - 20] |
debtEquityRatioTTM | 0.208 | -1.500 | 9.17 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.503 | 1.000 | 4.95 | 4.95 | [0.2 - 0.8] |
operatingProfitMarginTTM | -3.96 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -5.53 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.198 | 0.800 | -2.02 | -1.612 | [0.5 - 2] |
Total Score | -1.265 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.54 | 1.000 | -0.358 | 0 | [1 - 100] |
returnOnEquityTTM | -2.14 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.595 | 2.00 | -0.198 | -0.595 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.591 | 2.00 | -0.197 | -0.394 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0193 | 1.500 | -3.20 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.74 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.60 |
Veru Inc
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。